嵌合抗原受体T细胞疗法后胶质母细胞瘤的消退
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
作者信息
Brown Christine E, Alizadeh Darya, Starr Renate, Weng Lihong, Wagner Jamie R, Naranjo Araceli, Ostberg Julie R, Blanchard M Suzette, Kilpatrick Julie, Simpson Jennifer, Kurien Anita, Priceman Saul J, Wang Xiuli, Harshbarger Todd L, D'Apuzzo Massimo, Ressler Julie A, Jensen Michael C, Barish Michael E, Chen Mike, Portnow Jana, Forman Stephen J, Badie Behnam
机构信息
From the Department of Hematology and Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory (C.E.B., D.A., R.S., L.W., J.R.W., A.N., J.R.O., A.K., S.J.P., X.W., S.J.F.), and the Departments of Information Sciences (M.S.B.), Clinical Research (J.K., J.S.), Neurosurgery (T.L.H., M.C., B.B.), Pathology (M.D.), Diagnostic Radiology (J.A.R.), Developmental and Stem Cell Biology (M.E.B.), and Medical Oncology and Therapeutics Research (J.P.), City of Hope Beckman Research Institute and Medical Center, Duarte, CA; and the Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle (M.C.J.).
出版信息
N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497.
A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple infusions of CAR T cells were administered over 220 days through two intracranial delivery routes - infusions into the resected tumor cavity followed by infusions into the ventricular system. Intracranial infusions of IL13Rα2-targeted CAR T cells were not associated with any toxic effects of grade 3 or higher. After CAR T-cell treatment, regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid. This clinical response continued for 7.5 months after the initiation of CAR T-cell therapy. (Funded by Gateway for Cancer Research and others; ClinicalTrials.gov number, NCT02208362 .).
一名复发性多灶性胶质母细胞瘤患者接受了靶向肿瘤相关抗原白细胞介素-13受体α2（IL13Rα2）的嵌合抗原受体（CAR）工程化T细胞治疗。在220天内通过两种颅内给药途径多次输注CAR T细胞，即先向切除的肿瘤腔内输注，随后向脑室系统输注。颅内输注靶向IL13Rα2的CAR T细胞未出现3级或更高等级的任何毒性作用。CAR T细胞治疗后，观察到所有颅内和脊髓肿瘤均消退，同时脑脊液中细胞因子和免疫细胞水平相应升高。这种临床反应在CAR T细胞治疗开始后持续了7.5个月。（由癌症研究网关及其他机构资助；临床试验.gov编号，NCT02208362。）
Zotero 插件